收购人名称：兰州市人民政府国有资产监督管理委员会 收购人住所：兰州市城关区东岗西路 687 号 通讯地址：兰州市城关区东岗西路 687 号 签署日期：二零二三年八月 收购人声明 本声明所述的词语或简称与收购报告书"释义"部分所定义的词语或简称具 有相同的含义。 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 16 号 ——上市公司收购报告书》及相关的法律、法规及部门规章的有关规定编制。 兰州佛慈制药股份有限公司 收购报告书 上市公司名称：兰州佛慈制药股份有限公司 股票上市地点：深圳证券交易所 股票简称（A 股）：佛慈制药 股票代码（A 股）：002644 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》的规定， 本报告书已全面披露收购人在兰州佛慈制药股份有限公司拥有权益的股份。 截至本报告书签署日，除本报告书披露的相关信息外，收购人没有通过任何 其他方式在兰州佛慈制药股份有限公司拥有权益。 三、收购人签署本报告已获得必要的授权和批准，其 ...

上海市汇业律师事务所 关于兰州市人民政府国有资产监督管理委员会免于发出要约事宜 之法律意见书 上海市汇业律师事务所 关于兰州市人民政府国有资产监督管理委员会 免于发出要约事宜 之法律意见书 上海市汇业律师事务所 上海市延安西路 726 号 13 楼 C 座 电话：021-52370950 上海市汇业律师事务所 关于兰州市人民政府国有资产监督管理委员会免于发出要约事宜 之法律意见书 上 海 市 汇 业 律 师 事 务 所 H U I Y E L A W F I R M 上 海 市 延 安 西 路 7 2 6 号 1 3 楼 C 座 网 址 ： h t t p : / / w w w . h u i y e l a w . c o m 邮箱：o f f i c e @ h u i y e l a w . c o m 邮编：2 0 0 0 5 0 电话：021-52370950 上海市汇业律师事务所 关于兰州市人民政府国有资产监督管理委员会 免于发出要约事宜之法律意见书 汇业意字（2023）第 088 号 致：兰州市人民政府国有资产监督管理委员会 根据兰州市人民政府国有资产监督管理委员会（以下简称"兰州市国资委" ...

证券代码：002644 证券简称：佛慈制药 兰州佛慈制药股份有限公司 投资者关系活动记录表 | --- | --- | |---------------------|----------------------------------| | | □特定对象调研 | | 投资者关系 活动类别 | □媒体采访 □业绩说明会□新闻发布会 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | | | | | | | | | | | | | | | | 禧弘私募基金、point72 | | | 升、中加基金、野村东方国际、 | | | | | 参与单位 | | | 及人员 | | | | | | | | | | | | | | | | | | | | | | | | | 基金等共计 113 | | 时间 | 2023 年 8 月 6 日 | | 地点及方式 电话会议 | | | 上市公司 | | | 接待人员 | 文婷女士 | | --- | --- | |--------------|----------------------------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 609,032,829.06, representing a 31.89% increase compared to CNY 461,788,519.84 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 57,053,385.37, an increase of 11.35% from CNY 51,238,039.16 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 49,949,859.94, up 11.84% from CNY 44,662,803.52 year-on-year[21]. - The basic earnings per share increased to CNY 0.1117, reflecting a growth of 10.92% compared to CNY 0.1007 in the previous year[21]. - The total assets at the end of the reporting period were CNY 2,597,701,642.40, a slight increase of 0.43% from CNY 2,586,568,848.41 at the end of the previous year[21]. - The company reported a significant decrease in net cash flow from operating activities, which was negative CNY 50,236,281.89, compared to a positive CNY 47,966,453.73 in the same period last year, marking a decline of 204.73%[21]. - The weighted average return on net assets was 3.30%, slightly up from 3.11% in the previous year[21]. - The total net assets attributable to shareholders of the listed company increased to CNY 1,746,936,398.32, reflecting a growth of 1.84% from CNY 1,715,389,713.37 at the end of the previous year[21]. Research and Development - The company is committed to continuous R&D investment to enhance its innovation capabilities and product development[33]. - Research and development expenses surged by 73.54% to ¥14,909,087.27, up from ¥8,591,034.80, indicating a significant increase in R&D projects[49]. - The R&D expenditure for the first half of 2023 was 8.7 million yuan, accounting for approximately 6.2% of total revenue[151]. - The company aims to enhance its research and development efforts to drive innovation and maintain competitive advantage in the market[159]. Market Expansion and Strategy - The company is focusing on expanding its market presence beyond its base in Northwest China, enhancing brand competitiveness through strategic partnerships and marketing activities[37]. - The company is actively participating in major national conferences and events to increase brand awareness and product exposure[37]. - The company plans to enhance R&D capabilities and invest in innovative drug development to strengthen its core competitiveness[69]. - The company plans to continue expanding its market presence and invest in new product development in the upcoming quarters[151]. - The company expects a revenue growth of 10% for the second half of 2023, driven by new product launches and market expansion efforts[151]. Operational Efficiency - The company has implemented the "Amoeba" management model to improve operational efficiency and promote high-quality development[40]. - The company emphasizes the importance of optimizing management practices to adapt to its expanding business scale[71]. - The company aims to enhance its operational efficiency through strategic partnerships and potential acquisitions in the pharmaceutical sector[151]. - The company is adapting its procurement and production strategies to align with market demands and optimize cost efficiency[34]. Financial Health and Assets - The company's cash and cash equivalents decreased significantly to -¥77,572,139.46, a decline of 763.67% from a positive balance of ¥11,688,389.84 last year[49]. - The company's total liabilities increased to CNY 1,200,000,000.00 as of June 30, 2023, compared to CNY 1,000,000,000.00 as of June 30, 2022, indicating a growth of 20.0%[141]. - The total assets of the company at the end of the reporting period amounted to 4,443 million yuan, indicating a stable financial position[157]. - The total liabilities at the end of the reporting period were 1.2 billion yuan, indicating a manageable debt level[152]. Corporate Governance and Compliance - The annual shareholders meeting had a participation rate of 63.00% on April 20, 2023[74]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[75]. - The company has not engaged in any significant asset or equity sales during the reporting period[59]. - There were no significant lawsuits or arbitration matters during the reporting period[88]. - The company has no non-operating fund occupation by controlling shareholders or related parties[84]. Social Responsibility - The company actively engaged in poverty alleviation efforts, employing nearly 100 local farmers and benefiting over 2,000 households[81]. Risks and Challenges - The company faces risks from industry policy changes, raw material price fluctuations, and talent shortages, with strategies in place to mitigate these risks[66][67][68].

Group 1: Company Acquisition and Control - Gansu Guotou's acquisition of Foci Group is progressing with financial and legal due diligence ongoing [1] - The actual controller remains the Lanzhou Municipal Government's State-owned Assets Supervision and Administration Commission until the acquisition is completed [1] - Future development plans and potential new strategic investors will be clarified after the change of actual controller [1] Group 2: Market Expansion Strategy - The company aims to strengthen its presence in the Northwest market while expanding into East, South, and Southwest China through strategic partnerships [2] - International market expansion will leverage the company's overseas brand and resources, utilizing the Belt and Road Initiative to explore new sales models [2] Group 3: Key Product Development - The company has 467 product approval numbers and produces over 110 varieties, focusing on classic formulas and health products [2] - Major products include Liuwei Dihuang Wan, a proprietary formula for children's health, and other products targeting elderly diseases, aiming for over 100 million in revenue for key items [2] - The company plans to enhance market promotion for its unique products, including Ejiao and An Gong Niu Huang Wan, which are seeing increased market demand [2] Group 4: Strategic Goals and Growth - The company targets a revenue scale of 3 billion by 2025, with two-thirds of growth from internal development and one-third from external expansion [3] - Future acquisitions will focus on high-quality domestic companies that align with the company's strategic development [3] - The company is expanding its granule formula business, having established two subsidiaries for production and sales in Gansu [3] Group 5: Marketing and Personnel - The company currently employs over 400 marketing personnel, with plans to increase staff as it expands into new sales channels [3] - The company emphasizes compliance with information disclosure regulations during investor communications, highlighting the importance of investment risk awareness [3]

Financial Performance - The company's revenue for Q1 2023 was CNY 307,394,758.83, representing a 29.77% increase compared to CNY 236,878,872.61 in the same period last year[5] - Net profit attributable to shareholders was CNY 27,454,528.98, up 27.72% from CNY 21,496,460.61 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,201,984.94, reflecting a 29.17% increase from CNY 17,962,206.37 in the previous year[5] - Total operating revenue for Q1 2023 reached CNY 307,394,758.83, a 29.7% increase from CNY 236,878,872.61 in the same period last year[22] - Net profit for Q1 2023 was CNY 27,436,028.66, representing a 27.5% increase compared to CNY 21,545,308.08 in Q1 2022[23] - The total comprehensive income attributable to the parent company was CNY 27,454,528.98, compared to CNY 21,496,460.61 in the previous period, representing an increase of approximately 27.9%[24] Assets and Liabilities - The company's total assets increased by 4.67% to CNY 2,707,397,143.84 from CNY 2,586,568,848.41 at the end of the previous year[5] - Total liabilities increased to CNY 945,487,854.39, up from CNY 852,595,587.62 year-on-year[20] - The equity attributable to shareholders of the parent company rose to CNY 1,742,844,242.35, compared to CNY 1,715,389,713.37 in the previous year[20] - The company reported a total current asset of 1,416,547,234.24 RMB, an increase from 1,291,068,156.43 RMB at the beginning of the year, representing an increase of approximately 9.8%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -6,151,682.38, a decrease of 122.99% compared to CNY 26,757,794.43 in the same period last year[8] - Cash inflow from operating activities totaled CNY 281,429,158.62, up from CNY 198,038,162.63, marking a rise of about 42.0%[26] - Cash outflow from operating activities was CNY 287,580,841.00, compared to CNY 171,280,368.20 in the previous period, resulting in a net cash flow from operating activities of -CNY 6,151,682.38[26] - Investment activities resulted in a cash outflow of CNY 15,583,185.26, significantly higher than CNY 1,395,928.90 in the previous period, leading to a net cash flow from investment activities of -CNY 13,583,185.26[27] - Cash inflow from financing activities was CNY 500,000.00, while cash outflow was CNY 14,049,700.00, resulting in a net cash flow from financing activities of -CNY 13,549,700.00[27] - The ending balance of cash and cash equivalents decreased to CNY 354,400,479.61 from CNY 384,067,722.30, a decline of approximately 7.7%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 31,467[11] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, holds 61.63% of the shares, totaling 314,713,676 shares, with 150,000,000 shares pledged[11] - The company reported that the pledge of shares by the controlling shareholder accounts for 29.37% of the total share capital[13] Research and Development - Research and development expenses increased by 56.47% to CNY 6,296,817.19, up from CNY 4,024,334.17 year-on-year, indicating a focus on enhancing research collaboration[7] - Research and development expenses increased to CNY 6,296,817.19, up 56.5% from CNY 4,024,334.17 in the previous year[22] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[22] Management and Operational Costs - The company's management expenses rose by 59.44% to CNY 20,733,888.20, attributed to increased depreciation costs[7] - Total operating costs amounted to CNY 281,431,478.22, up 33% from CNY 211,498,791.15 year-on-year[22] Changes in Control - The controlling shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, is undergoing a change in actual control, with Gansu State-owned Assets Investment Group intending to acquire 100% of its equity[14] - Gansu State-owned Assets Investment Group will indirectly hold 61.63% of the company's issued shares post-acquisition, triggering a mandatory tender offer for the remaining shares[15] - The tender offer price is set at 9.60 RMB per share, covering 195,943,324 shares, which is 38.37% of the company's issued shares[15] - The company is actively progressing with the necessary audits and approvals for the change in control, which carries certain uncertainties[16] Other Information - The company reported a government subsidy of CNY 5,059,784.65, contributing to its non-recurring gains[6] - The company reported an investment income of CNY 612,806.12, indicating a positive contribution from investments[23] - The company did not undergo an audit for the first quarter report[28] - The report was presented by the board of directors on April 25, 2023[29]

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20230412 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 √业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 及人员名称 | 参与公司 2022 年度业绩说明会的投资者 | | 时间 2023 | 年 月 日 4 12 15:00—17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net/zj） | | 形式 | □现场 √ 网上 □电话会议 | | 公司接待 | 董事长石爱国先生，董事、副总经理王迎春先生，独立董事龙 | | 人员姓名 | 凤鸣女士，董事会秘书王军辉先生，财务总监岳金风女士。 | | | 公司在全景网"投资者关系互动平台"采用网络远程的方 | | | 式举行了 2022 年度业绩说明会，公司相关人员与参会投资者 | | | 进行了充分的沟通交流，主要交流问题及回复如下： | | | 1. 公司当时说加班加点生产抗病毒药，一季度什么情况？ | | | ...

证券代码：002644 证券简称：佛慈制药 公告编号：2023-014 兰州佛慈制药股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日披露 了《2022 年年度报告》。为便于广大投资者更深入全面地了解公司 2022 年年度 报告和经营情况，公司将于 2023 年 4 月 12 日（星期三）15:00—17:00 在全景网 举办 2022 年度业绩说明会。本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net/zj）参与本次年度 业绩说明会。 出席本次说明会的人员有：公司董事长石爱国先生，董事、副总经理王迎春 先生，独立董事龙凤鸣女士，董事会秘书王军辉先生，财务总监岳金风女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 11 日（星期二）12：0 ...